AI assistant
SCIDEV LTD — Interim / Quarterly Report 2021
Feb 7, 2021
65761_rns_2021-02-07_e74950ca-c4ea-493c-86b8-3148ceccfa6b.pdf
Interim / Quarterly Report
Open in viewerOpens in your device viewer
Unit 1 8 Turbo Road Kings Park NSW 2148 Australia ABN 25 001 150 849
Email: [email protected] Website: www.scidev.com.au ASX code: SDV
8 February 2021
SciDev delivers inaugural net profit of A$0.4m
SciDev Ltd (ASX: SDV) ('SciDev' or 'the Company') is pleased to provide its results for the half-year period ending 31 December 2020.
1HFY21 Financial Highlights
- Reported half year net profit of A$0.4m (1HFY20 -A$0.2m)
- Record half year results;
- sales of A$18.3m (+300% vs 1HFY20 A$6.1m)
- cash receipts from customers of A$15.8m (+290% vs 1HFY20 A$3.8m)
- Net cash at the end of the period of A$7.1m
- Strong gross profit margin of 23% (FY20 17%)
1HFY21 Operational Highlights
- Strong development pipeline with field qualifications underway across all sectors
- Expansion into the infrastructure sector providing opportunities for global growth
- Strong revenue growth in mining sector with sales to a range of blue-chip customers
- New offerings in Oil & Gas with strong momentum as activities continue to rebound
Reflecting on the Company's performance of 1HFY21, SciDev Managing Director and Chief Executive Officer Lewis Utting said: 'It is pleasing to deliver a profit over this period. The strong revenue growth we delivered is a positive reflection of the continued work from the SciDev team and the growing acknowledgement and appreciation from the market for our bespoke products and technology.
Importantly, we are continuing to progress towards cashflow sustainability. The Company delivered a positive net cashflow from operations of A$1.8m in the second quarter. With our growth pipeline and strong gross profit margin we will continue to push towards positive cash generation over the remainder of FY21.
Our strong balance sheet is strong with a net cash position of A$7m provides an opportunity for the Company to execute on our business development initiatives as well as seek other avenues for growth.
I would like to thank the SciDev team for their efforts over the period as we look forward to continued success and delivering on a range of growth opportunities over the coming quarters.'
Financial Review
Revenue for 1HFY21 of A$18.3m (1HFY20: A$6.1) reflects business development growth across all the Company'sfour sectors of Mining & Mineral Processing, Oil & Gas, Construction & Infrastructure, and Water & Wastewater. The continued growth in the Oil & Gas sector, as drilling activities continued to rebound, delivered A$6.9m salesfor the half year. Mining & Mineral processing sales delivered A$7.2m the half year as the Company continues to grow sales into long-term supply agreements with a range of blue-chip customers such as BHP Billiton, Iluka and MMG. Sales into the construction sector added $A3.1m to the revenue growth over the period. Activities in Water & Wastewater were broadly in line with the previous period as evaluations of SciDev chemistry continue to be on hold pending improved COVID-19 pandemic outlook.
| Mining &MineralProcessing | Oil & Gas | Construction &Infrastructure | Water &Wastewater | Total | |
|---|---|---|---|---|---|
| 1HFY21Sector revenue(A$m) | A$7.2 | A$6.9 | A$3.1 | A$1.1 | A$18.3 |
| % of TotalRevenue | 39% | 38% | 17% | 6% |
Cash receipts were A$15.8m for the half, a considerable uplift on 1H20 levels of A$3.8m. Despite the strong uplift in cash receipts, cash from operating activities was (A$4.6m) for the period. The negative operating cashflow is reflective of timing differences between revenue and costs and a product inventory build as the Company gears up to deliver on growth.
At the end of the half the Company had trade receivables of A$5.5m and trade payables of A$5.1m. Whilst operating cashflow for the half was negative, the Company delivered A$1.8m of cash flow from operations for the second quarter, the Company remains committed to delivering positive cashflow.
Cash at bank at the end of the period was A$7.1m (A$3.1m at 31 December 2019). The Company ended the period with A$3.5m of inventory on hand. Gross profit margin for the period was 23% representing a 35% increase on 1HFY20. Gross profit margin is anticipated to normalise in the range of 20-30%.
Outlook
Management focus for the remainder of FY21 will be:
- Ongoing focus on the health and safety of our employees and stakeholders
- Continued focus on increasing sales and cash conversion in all regions]
- Capitalise on our position and market recovery in the North American Oil & Gas sector
- Drive additional growth in infrastructure sector locally and globally
- Progress commercial discussions post field validation across several BD opportunities
- Continue discussions with technology partners in North America and Europe
- Ongoing assessment of strategic growth opportunities globally
Lewis Utting Managing Director & Chief Executive Officer
This release has been approved by the Board of Directors of SciDev Limited.
For Further Information:
| Corporate | Investors |
|---|---|
| Lewis Utting –MD & CEO | Craig Sainsbury –Market Eye |
| Heath Roberts –Company Secretary | [email protected] |
| +61 2 9622 5185 | +61 428 550 499 |
About SciDev
SciDev is a leader in the development and application of both chemistry and process control for solids- liquid separation. SciDev brings together world-class technology, chemistry, management and manufacturing capabilities to solve pressing operational and environmental issues for the water, oil and gas, mining and construction markets.
SciDev Limited Appendix 4D Half-year report
1. Company details
| Name of entity: | SciDev Limited |
|---|---|
| ABN: | 25 001 150 849 |
| Reporting period: | For the half-year ended 31 December 2020 |
| Previous period: | For the half-year ended 31 December 2019 |
2. Results for announcement to the market
| $ | |||
|---|---|---|---|
| Revenues from ordinary activities | up | 200% to | 18,332,647 |
| Profit from ordinary activities after tax attributable to the owners ofSciDev Limited | up | 324% to | 427,450 |
| Profit for the half-year attributable to the owners of SciDev Limited | up | 324% to | 427,450 |
Dividends
There were no dividends paid, recommended or declared during the current financial period.
Comments
The profit for the consolidated entity after providing for income tax amounted to $427,450 (31 December 2019: loss of $191,233).
Reference is made to the Review of Operations in the Directors' Report contained in the attached Interim Financial Report for SciDev Limited for the half-year ended 31 December 2020.
3. Net tangible assets
| ReportingperiodCents | PreviousperiodCents | |
|---|---|---|
| Net tangible assets per ordinary security | 8.69 | 4.30 |
4. Control gained over entities
Not applicable.
5. Loss of control over entities
Not applicable.
6. Dividends
Current period
There were no dividends paid, recommended or declared during the current financial period.
Previous period
There were no dividends paid, recommended or declared during the previous financial period.
7. Dividend reinvestment plans
Not applicable.
8. Details of associates and joint venture entities
Not applicable.
9. Foreign entities
Details of origin of accounting standards used in compiling the report:
Not applicable.
10. Audit qualification or review
Details of audit/review dispute or qualification (if any):
The financial statements were subject to a review by the auditors and the review report is attached as part of the Interim Report.
11. Attachments
Details of attachments (if any):
The Interim Report of SciDev Limited for the half-year ended 31 December 2020 is attached.
12. Signed
Date: 5 February 2021 Lewis Utting, Managing Director and Chief Executive Officer for and on behalf of the Board
SciDev Limited
ABN 25 001 150 849
Interim Report - 31 December 2020
SciDev Limited Corporate directory 31 December 2020
| Directors | Trevor A Jones - ChairmanLewis E Utting - Managing DirectorSimone Watt - Non-executive DirectorJon Gourlay - Non-executive Director |
|---|---|
| Company secretary | Heath L Roberts |
| Registered office | C/-Boardroom Pty LimitedLevel 12, Grosvenor Place225 George Street, SydneyNSW 2000Phone: 1300 737 760 |
| Principal place of business | Unit 18 Turbo RoadKings ParkNSW 2148Phone: (02) 9622 5185 |
| Share register | Boardroom Pty LimitedLevel 12225 George Street, SydneyNSW 2000Phone: 1300 737 760 |
| Auditor | Rothsay Chartered AccountantsLevel12 O'Connell StreetSydneyNSW 2000 |
| Stock exchange listing | SciDev Limited shares are listed on the Australian Securities Exchange (ASX code:SDV) |
| Website | www.scidev.com.au |
| Corporate Governance Statement | www.scidev.com.au/corporate-governance |
SciDev Limited Directors' report 31 December 2020
The directors present their report, together with the financial statements, on the consolidated entity (referred to hereafter as the 'consolidated entity') consisting of SciDev Limited (referred to hereafter as the 'company' or 'parent entity') and the entities it controlled at the end of, or during, the half-year ended 31 December 2020.
Directors
The following persons were directors of SciDev Limited during the whole of the financial half-year and up to the date of this report, unless otherwise stated:
Trevor A Jones - Chairman Lewis E Utting - Managing Director Simone Watt - Non-executive Director Jon Gourlay - Non-executive Director
Principal activities
The principal activity of the consolidated entity is delivery of process control, professional services and chemistry in the Mining, Construction, Water treatment and Oil & Gas markets.
Dividends
There were no dividends paid, recommended or declared during the current or previous financial half-year.
Review of operations
Revenue for 1H FY21 of AUD$18.3million (1H FY20: AUD$6.1 million) reflecting ongoing sales into existing customers and development activities.
The consolidated entity revenues grew in all four customer sectors, Mining & Mineral Processing, Oil & Gas, Construction & Infrastructure, and Water & Wastewater. Revenue growth has been driven by expansion into the construction sector, USA Oil & Gas, field validation work in the Canadian oil sands, BHP Olympic Dam and with several other target clients.
1H FY21 profit for the consolidated entity after providing for income tax amounted to AUD$427,450 (31 December 2019: loss of AUD$191,233).
The consolidated entity 1H FY21 cash receipts are AUD$15.8 million (1H FY20: AUD$3.8 million), with trade receivables of AUD$5.5 million and trade payables of AUD$5.1 million.
Net cash inflow from operations in Q2 FY21 was AUD$1.8 million, net cash flow from operations for 1H FY21 was -$4.2 million. The consolidated entity strengthened its supply chain engagement which is reflected in DSO improvement of 10% Qtr on Qtr.
Cash at Bank at the end of the period was AUD$7.1 million (1H FY20 AUD$2.8 million).
Gross profit margin for the period was 23% representing a 29% increase on FY20 result.
Reconciliation of profit/(loss) before income tax to EBITDA:
| Consolidated | |||
|---|---|---|---|
| 31 Dec 2020$ | 31 Dec 2019$ | ||
| Profit/(loss) before income tax expense | 580,580 | (191,233) | |
| Depreciation and amortisation | 268,989 | 137,627 | |
| Interest revenue | (923) | (2,331) | |
| Finance costs | 90,159 | 35,133 | |
| EBITDA | 938,805 | (20,804) |
EBITDA is a non-IFRS earnings measure which does not have any standardised meaning prescribed by IFRS and therefore may not be comparable to EBITDA presented by other companies. This measure, which has not been audited or reviewed by the company's external auditor, is important to management as an additional way to evaluate the consolidated entity's performance.
SciDev Limited Directors' report 31 December 2020
Significant changes in the state of affairs
There were no significant changes in the state of affairs of the consolidated entity during the financial half-year.
Matters subsequent to the end of the financial half-year
No matter or circumstance has arisen since 31 December 2020 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.
Auditor's independence declaration
A copy of the auditor's independence declaration as required under section 307C of the Corporations Act 2001 is set out immediately after this directors' report.
This report is made in accordance with a resolution of directors, pursuant to section 306(3)(a) of the Corporations Act 2001.
On behalf of the directors.
___________________________
Lewis Utting Managing Director
5 February 2021 Sydney

AUDITOR'S INDEPENDENCE DECLARATION UNDER SECTION 307C OF THE CORPORATIONS ACT 2001
As lead auditor of SciDev Limited for the half year ended 31 December 2020, I declare that, to the best of my knowledge and belief, there have been:
- no contraventions of the auditor independence requirements of the Corporations Act 2001 in relation to the audit; and
- no contraventions of any applicable code of professional conduct in relation to the audit.
This declaration is in respect of SciDev Limited and the entities it controlled during the year.
Rothsay Chartered Accountants
Frank Vrachas Partner Sydney, 02 February 2021

SciDev Limited Contents 31 December 2020
| Statement of profit or loss and other comprehensive income | 6 |
|---|---|
| Statement of financial position | 7 |
| Statement of changes in equity | 8 |
| Statement of cash flows | 9 |
| Notes to the financial statements | 10 |
| Directors' declaration | 18 |
| Independent auditor's review report to the members of SciDev Limited | 19 |
General information
The financial statements cover SciDev Limited as a consolidated entity consisting of SciDev Limited and the entities it controlled at the end of, or during, the half-year. The financial statements are presented in Australian dollars, which is SciDev Limited's functional and presentation currency.
SciDev Limited is a listed public company limited by shares, incorporated and domiciled in Australia. Its registered office and principal place of business are:
Registered office Principal place of business C/- Boardroom Pty Limited Unit 1 Level 12 8 Turbo Road 225 George Street Kings Park Sydney NSW 2148 NSW 2000
A description of the nature of the consolidated entity's operations and its principal activities are included in the directors' report, which is not part of the financial statements.
The financial statements were authorised for issue, in accordance with a resolution of directors, on 5 February 2021.
SciDev Limited Statement of profit or loss and other comprehensive income For the half-year ended 31 December 2020
| Consolidated | |||
|---|---|---|---|
| Note | 31 Dec 2020$ | 31 Dec 2019$ | |
| Revenue | 3 | 18,332,647 | 6,118,308 |
| Other incomeInterest revenue | 4 | 545,538923 | 31,1482,331 |
| ExpensesChanges in inventories, and raw materials and consumables usedEmployee benefits expenseDepreciation and amortisation expense | (13,364,146)(2,465,899)(268,989) | (4,264,671)(739,796)(137,627) | |
| Engineering and other consultants expensesImpairment of assetsWrite off of assets | (370,632)-(25,300) | (114,304)(3,496)- | |
| InsuranceListing and share registry expensesForeign exchange losses | (114,420)(50,015)(161,221) | (42,628)(98,656)- | |
| Professional feesRent and related expensesTravel, accommodation and conference | (209,690)(180,030)(128,599) | (404,336)(43,372)(159,749) | |
| Other expensesFinance costs | (869,428)(90,159) | (299,252)(35,133) | |
| Profit/(loss) before income tax expense | 580,580 | (191,233) | |
| Income tax expense | (153,130) | - | |
| Profit/(loss) after income tax expense for the half-year attributable to theowners of SciDev Limited | 427,450 | (191,233) | |
| Other comprehensive income | |||
| Items that may be reclassified subsequently to profit or lossForeign currency translation | 5,408 | (106,918) | |
| Other comprehensive income for the half-year, net of tax | 5,408 | (106,918) | |
| Total comprehensive income for the half-year attributable to the owners ofSciDev Limited | 432,858 | (298,151) | |
| Cents | Cents | ||
| Basic earnings per shareDiluted earnings per share | 1818 | 0.280.28 | (0.16)(0.16) |
SciDev Limited Statement of financial position As at 31 December 2020
| Consolidated | |||
|---|---|---|---|
| Note | 31 Dec 2020$ | 30 June 2020$ | |
| Assets | |||
| Current assets | |||
| Cash and cash equivalents | 5 | 7,107,807 | 4,481,783 |
| Trade and other receivables | 6 | 5,620,394 | 2,170,036 |
| Inventories | 7 | 3,567,713 | 4,805,023 |
| Income tax refund due | 3,049 | 32,623 | |
| Other | 448,011 | 153,254 | |
| Total current assets | 16,746,974 | 11,642,719 | |
| Non-current assets | |||
| Financial assets at fair value through other comprehensive income | 1,502,900 | 1,502,900 | |
| Property, plant and equipment | 8 | 1,518,467 | 1,196,808 |
| Intangibles | 9 | 11,473,513 | 11,402,074 |
| Deferred tax | 1,211,232 | 1,364,362 | |
| Other | 39,706 | 64,053 | |
| Total non-current assets | 15,745,818 | 15,530,197 | |
| Total assets | 32,492,792 | 27,172,916 | |
| Liabilities | |||
| Current liabilities | |||
| Trade and other payables | 10 | 5,837,764 | 8,500,186 |
| Contract liabilities | 2,484 | - | |
| Borrowings | 11 | 656,965 | - |
| Lease liabilities | 12 | 387,679 | 182,780 |
| Employee benefits | 167,505 | 126,448 | |
| Provisions | 13 | 313,500 | 285,258 |
| Total current liabilities | 7,365,897 | 9,094,672 | |
| Non-current liabilities | |||
| Borrowings | 11 | 252,792 | 284,918 |
| Lease liabilities | 12 | 112,049 | 70,655 |
| Provisions | 13 | - | 313,500 |
| Total non-current liabilities | 364,841 | 669,073 | |
| Total liabilities | 7,730,738 | 9,763,745 | |
| Net assets | 24,762,054 | 17,409,171 | |
| Equity | |||
| Issued capital | 14 | 97,054,733 | 89,874,533 |
| Other equity | 15 | 307,800 | 569,975 |
| Reserves | 16 | 140,085 | 132,677 |
| Accumulated losses | (72,740,564) | (73,168,014) | |
| Total equity | 24,762,054 | 17,409,171 |
SciDev Limited Statement of changes in equity For the half-year ended 31 December 2020
| Consolidated | Issuedcapital$ | Reserves$ | Accumulatedlosses$ | Total equity$ | |
|---|---|---|---|---|---|
| Balance at 1 July 2019 | 76,899,789 | 2,210,703 | (74,411,471) | 4,699,021 | |
| Loss after income tax expense for the half-yearOther comprehensive income for the half-year, net of tax | -- | -(106,918) | (191,233)- | (191,233)(106,918) | |
| Total comprehensive income for the half-year | - | (106,918) | (191,233) | (298,151) | |
| Transactions with owners in their capacity as owners:Contributions of equity, net of transaction costs | 5,314,899 | - | - | 5,314,899 | |
| Balance at 31 December 2019 | 82,214,688 | 2,103,785 | (74,602,704) | 9,715,769 | |
| Consolidated | Issuedcapital$ | Otherequity$ | Reserves$ | Accumulatedlosses$ | Total equity$ |
| Balance at 1 July 2020 | 89,874,533 | 569,975 | 132,677 | (73,168,014) | 17,409,171 |
| Profit after income tax expense for the halfyearOther comprehensive income for the half-year,net of tax | -- | -- | -5,408 | 427,450- | 427,4505,408 |
| Total comprehensive income for the half-year | - | - | 5,408 | 427,450 | 432,858 |
| Transactions with owners in their capacity asowners:Contributions of equity, net of transaction costs(note 14)Share-based payments (note 19) | 7,180,200- | (262,175)- | -2,000 | -- | 6,918,0252,000 |
| Balance at 31 December 2020 | 97,054,733 | 307,800 | 140,085 | (72,740,564) | 24,762,054 |
8
SciDev Limited Statement of cash flows For the half-year ended 31 December 2020
| Consolidated | |||
|---|---|---|---|
| Note | 31 Dec 2020$ | 31 Dec 2019$ | |
| Cash flows from operating activities | |||
| Receipts from customers (inclusive of GST) | 15,864,650 | 3,818,376 | |
| Payments to suppliers and employees (inclusive of GST) | (20,520,232) | (6,311,163) | |
| (4,655,582) | (2,492,787) | ||
| Government grants and subsidies | 105,501 | - | |
| Interest received | 923 | 2,331 | |
| R&D tax offset received | 380,361 | - | |
| Interest and other finance costs paid | (90,159) | (35,133) | |
| Income taxes refunded | 29,574 | - | |
| Net cash used in operating activities | (4,229,382) | (2,525,589) | |
| Cash flows from investing activities | |||
| Payment for purchase of business, net of cash acquired | - | (926,438) | |
| Payments for property, plant and equipment | 8 | (270,239) | (161,399) |
| Payments for intangibles | 9 | (119,119) | (28,113) |
| Payments for contingent consideration | 13 | (267,031) | - |
| Proceeds from disposal of property, plant and equipment | 52,747 | - | |
| Proceeds from release of security deposits | 22,937 | - | |
| Net cash used in investing activities | (580,705) | (1,115,950) | |
| Cash flows from financing activities | |||
| Proceeds from issue of shares | 14 | 7,000,000 | 4,972,899 |
| Proceeds from borrowings | 817,639 | - | |
| Proceeds from exercise of share options | 110,000 | - | |
| Share issue transaction costs | (191,975) | - | |
| Repayment of borrowings and lease liabilities | (290,046) | (10,983) | |
| Net cash from financing activities | 7,445,618 | 4,961,916 | |
| Net increase in cash and cash equivalents | 2,635,531 | 1,320,377 | |
| Cash and cash equivalents at the beginning of the financial half-year | 4,481,783 | 1,756,209 | |
| Effects of exchange rate changes on cash and cash equivalents | (9,507) | - | |
| Cash and cash equivalents at the end of the financial half-year | 5 | 7,107,807 | 3,076,586 |
Note 1. Significant accounting policies
These general purpose financial statements for the interim half-year reporting period ended 31 December 2020 have been prepared in accordance with Australian Accounting Standard AASB 134 'Interim Financial Reporting' and the Corporations Act 2001, as appropriate for for-profit oriented entities. Compliance with AASB 134 ensures compliance with International Financial Reporting Standard IAS 34 'Interim Financial Reporting'.
These general purpose financial statements do not include all the notes of the type normally included in annual financial statements. Accordingly, these financial statements are to be read in conjunction with the annual report for the year ended 30 June 2020 and any public announcements made by the company during the interim reporting period in accordance with the continuous disclosure requirements of the Corporations Act 2001.
The principal accounting policies adopted are consistent with those of the previous financial year and corresponding interim reporting period, unless otherwise stated.
New or amended Accounting Standards and Interpretations adopted
The consolidated entity has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period. The adoption of these Accounting Standards and Interpretations did not have any significant impact on the financial performance or position of the consolidated entity.
Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.
Note 2. Operating segments
Identification of reportable operating segments
The consolidated entity operates in primarily two geographical segments: Australia and the United States. In the 31 December 2019 financial half-year the consolidated entity operated in primarily one geographical segment being Australia and revenue attributable to overseas subsidiaries was not material to the consolidated entity. The primary business segment is the treatment of industrial waste including the manufacture and supply of chemicals for the treatment of waste water.
Operating and business segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing the performance of the operating segments, has been identified as the Board of Directors.
Intersegment transactions
Intersegment transactions were made at market rates. Intersegment transactions are eliminated on consolidation.
SciDev Limited Notes to the financial statements 31 December 2020
Note 2. Operating segments (continued)
Operating segment information
| Eliminations | ||||
|---|---|---|---|---|
| Australia | United States | andadjustments | Total | |
| Consolidated - 31 Dec 2020 | $ | $ | $ | $ |
| Revenue | ||||
| Sales to external customers | 11,332,519 | 6,854,442 | - | 18,186,961 |
| Intersegment sales | - | 73,210 | (73,210) | - |
| Total sales revenue | 11,332,519 | 6,927,652 | (73,210) | 18,186,961 |
| Other revenue | 16,868 | 128,818 | - | 145,686 |
| Interest revenue | 923 | - | - | 923 |
| Total revenue | 11,350,310 | 7,056,470 | (73,210) | 18,333,570 |
| EBITDA | 1,368,422 | (429,617) | - | 938,805 |
| Depreciation and amortisation | (268,989) | |||
| Interest revenue | 923 | |||
| Finance costs | (90,159) | |||
| Profit before income tax expense | 580,580 | |||
| Income tax expense | (153,130) | |||
| Profit after income tax expense | 427,450 | |||
| Note 3. Revenue | ||||
| Consolidated | ||||
| 31 Dec 2020$ | 31 Dec 2019$ | |||
| Revenue from contracts with customers | ||||
| Treatment fees and product sales | 18,186,961 | 6,082,916 | ||
| Other revenue | ||||
| Other | 145,686 | 35,392 | ||
| Revenue | 18,332,647 | 6,118,308 | ||
| Note 4. Other income | ||||
| Consolidated | ||||
| 31 Dec 2020 | 31 Dec 2019 | |||
| $ | $ | |||
| Net foreign exchange gain | - | 31,148 | ||
| Net gain on disposal of property, plant and equipment | 15,337 | - | ||
| Subsidies and grants | 512,847 | - | ||
| Sundry | 17,354 | - | ||
| Other income | 545,538 | 31,148 | ||
SciDev Limited Notes to the financial statements 31 December 2020
Note 5. Cash and cash equivalents
| Consolidated | ||
|---|---|---|
| 31 Dec 2020$ | 30 June 2020$ | |
| Current assets | ||
| Cash at bank | 7,107,807 | 4,481,783 |
| Note 6. Trade and other receivables | ||
| Consolidated | ||
| 31 Dec 2020$ | 30 June 2020$ | |
| Current assets | ||
| Trade receivables | 5,593,187 | 2,111,383 |
| Other receivables | 27,207 | 58,653 |
| 5,620,394 | 2,170,036 | |
| Note 7. Inventories | ||
| Consolidated | ||
| 31 Dec 2020 | 30 June 2020 | |
| $ | $ | |
| Current assets | ||
| Stock in transit - at cost | - | 547,877 |
| Stock on hand - at cost | 3,567,713 | 4,257,146 |
| 3,567,713 | 4,805,023 | |
| Note 8. Property, plant and equipment | ||
| Consolidated | ||
| 31 Dec 2020 | 30 June 2020 | |
| $ | $ | |
| Non-current assets | ||
| Office buildings and warehouses - at cost | 513,932 | 186,480 |
| Less: Accumulated depreciation | (174,204) | (86,068) |
| 339,728 | 100,412 | |
| Plant and equipment - at cost | 2,037,365 | 2,204,673 |
| Less: Accumulated depreciation | (1,013,523) | (1,247,984) |
| 1,023,842 | 956,689 | |
| Motor vehicles - at cost | 303,888 | 284,340 |
| Less: Accumulated depreciation | (164,049) | (164,395) |
| 139,839 | 119,945 | |
| Office equipment - at cost | 30,063 | 61,090 |
| Less: Accumulated depreciation | (15,005) | (41,328) |
| 15,058 | 19,762 | |
| 1,518,467 | 1,196,808 | |
Note 8. Property, plant and equipment (continued)
Reconciliations
Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:
| Consolidated | Officebuildings andwarehouses$ | Plant andequipment$ | Motorvehicles$ | Officeequipment$ | Total$ |
|---|---|---|---|---|---|
| Balance at 1 July 2020 | 100,412 | 956,689 | 119,945 | 19,762 | 1,196,808 |
| Additions | - | 270,239 | - | - | 270,239 |
| Disposals | - | (28,202) | (9,208) | - | (37,410) |
| Adjustments | - | 1,503 | (25) | - | 1,478 |
| Exchange differences | 3,186 | (33,957) | (8,093) | - | (38,864) |
| Recognition of right of use asset | 327,452 | - | 53,844 | - | 381,296 |
| Depreciation expense | (91,322) | (142,430) | (16,624) | (4,704) | (255,080) |
| Balance at 31 December 2020 | 339,728 | 1,023,842 | 139,839 | 15,058 | 1,518,467 |
Included in the above line items are right-of-use assets over the following:
| Officebuildings andwarehouses$ | Motorvehicles$ | Total$ | |
|---|---|---|---|
| Balance at 1 July 2020 | 100,412 | 101,393 | 201,805 |
| Recognition of right-of-use asset | 327,452 | 53,844 | 381,296 |
| Exchange differences | 3,186 | (7,559) | (4,373) |
| Depreciation expense | (91,322) | (11,410) | (102,732) |
| Balance at 30 June 2020 | 339,728 | 136,268 | 475,996 |
Note 9. Intangibles
| Consolidated | |||
|---|---|---|---|
| 31 Dec 2020$ | 30 June 2020$ | ||
| Non-current assets | |||
| Goodwill - at cost | 10,987,134 | 10,987,134 | |
| Trade marks and intellectual property - at cost | 742,958 | 670,125 | |
| Less: Accumulated amortisation | (256,579) | (255,185) | |
| 486,379 | 414,940 | ||
| 11,473,513 | 11,402,074 |
SciDev Limited Notes to the financial statements 31 December 2020
Note 9. Intangibles (continued)
Reconciliations
Reconciliations of the written down values at the beginning and end of the current financial half-year are set out below:
| Trade marksandintellectual | ||||
|---|---|---|---|---|
| Consolidated | Goodwill | property | Total | |
| $ | $ | $ | ||
| Balance at 1 July 2020 | 10,987,134 | 414,940 | 11,402,074 | |
| Additions | - | 119,119 | 119,119 | |
| Exchange differences | - | (8,471) | (8,471) | |
| Write off of assets | - | (25,300) | (25,300) | |
| Amortisation expense | - | (13,909) | (13,909) | |
| Balance at 31 December 2020 | 10,987,134 | 486,379 | 11,473,513 |
Note 10. Trade and other payables
| Consolidated31 Dec 2020$ | 30 June 2020$ | |
|---|---|---|
| Current liabilities | ||
| Trade payables | 5,165,850 | 7,823,591 |
| BAS payable | 136,024 | 238,775 |
| Other payables | 535,890 | 437,820 |
| 5,837,764 | 8,500,186 | |
| Note 11. Borrowings |
| Consolidated31 Dec 202030 June 2020$$ | ||
|---|---|---|
| Current liabilitiesDebtor factoring facility | 656,965 | - |
| Non-current liabilitiesLoan - Paycheck Protection Program (USA) | 252,792284,918 | |
| 909,757284,918 |
SciDev Limited Notes to the financial statements 31 December 2020
Note 12. Lease liabilities
| 31 Dec 2020$ | Consolidated30 June 2020$ | |
|---|---|---|
| Current liabilitiesLease liability - land and buildings | 340,999 | 89,574 |
| Lease liability - motor vehicles | 46,680387,679 | 93,206182,780 |
| Non-current liabilitiesLease liability - land and buildingsLease liability - motor vehicles | 7,730104,319 | 15,59455,061 |
| 112,049 | 70,655 | |
| 499,728 | 253,435 | |
| Note 13. Provisions | ||
| 31 Dec 2020$ | Consolidated30 June 2020$ | |
| Current liabilitiesContingent considerationWarranties | 313,500- | 267,03118,227 |
| 313,500 | 285,258 |
| Non-current liabilities | ||
|---|---|---|
| Contingent consideration | - | 313,500 |
| 313,500 | 598,758 |
The deferred consideration provision represents the obligation to pay contingent consideration in connection with the acquisition of ProSol Australia Pty Ltd. It is measured at the present value of the estimated liability.
Note 14. Issued capital
| Consolidated | ||||
|---|---|---|---|---|
| 31 Dec 2020Shares | 30 June 2020Shares | 31 Dec 2020$ | 30 June 2020$ | |
| Ordinary shares - fully paid | 153,145,242 | 140,889,052 | 97,054,733 | 89,874,533 |
Note 14. Issued capital (continued)
Movements in ordinary share capital
| Details | Date | Shares | Issue price | $ |
|---|---|---|---|---|
| Balance | 1 July 2020 | 140,889,052 | 89,874,533 | |
| Share placement | 24 July 2020 | 7,692,308 | $0.65 | 5,000,000 |
| Options exercised | 29 July 2020 | 125,000 | $0.12 | 15,000 |
| Shares issued to the vendor of ProSol Australia Pty | ||||
| Ltd | 29 July 2020 | 436,959 | $0.60 | 262,175 |
| Share purchase plan | 21 August 2020 | 3,076,923 | $0.65 | 2,000,000 |
| Options exercised | 17 November 2020 | 800,000 | $0.10 | 80,000 |
| Options exercised | 26 November 2020 | 125,000 | $0.12 | 15,000 |
| Share issue expenses | - | $0.00 | (191,975) | |
| Balance | 31 December 2020 | 153,145,242 | 97,054,733 |
Share placement and share purchase plan
On 24 July 2020 SciDev Limited announced the placement of 7,692,308 new ordinary shares with two leading Australian Fund Managers at an issue price of $0.65 per share.
On 21 August 2020 SciDev Limited announced that it had issued 3,076,923 new ordinary shares at $0.65 per share pursuant to a Share Purchase Plan (SPP).
The net proceeds from the Share Placement and the SPP were used to fund a range of organic and inorganic business growth opportunities.
Shares issued to the vendor of ProSol Australia Pty Ltd
On 29 July 2020 SciDev Limited issued 436,959 ordinary shares to the vendor of ProSol Australia Pty Ltd (ProSol) being part of the first tranche of milestoned consideration under the terms of acquisition of ProSol (see note 15).
Note 15. Other equity
| Consolidated | ||
|---|---|---|
| 31 Dec 2020$ | 30 June 2020$ | |
| Contingent consideration | 307,800 | 569,975 |
The contingent consideration relates to the acquisition of ProSol Pty Ltd and represents the fair value of the consideration to be settled by the issue of SciDev Ltd shares.
| Consolidated | ||
|---|---|---|
| 31 Dec 2020$ | 30 June 2020$ | |
| Opening balanceAcquisition of ProSol Pty LtdIssue of shares | 569,975-(262,175) | -569,975- |
| Closing balance | 307,800 | 569,975 |
SciDev Limited Notes to the financial statements 31 December 2020
Note 16. Reserves
| Consolidated | |||
|---|---|---|---|
| 31 Dec 2020$ | 30 June 2020$ | ||
| Foreign currency reserveShare-based payments reserve | (30,902)170,987 | (36,310)168,987 | |
| 140,085 | 132,677 |
Note 17. Events after the reporting period
No matter or circumstance has arisen since 31 December 2020 that has significantly affected, or may significantly affect the consolidated entity's operations, the results of those operations, or the consolidated entity's state of affairs in future financial years.
Note 18. Earnings per share
| Consolidated31 Dec 2020$ | 31 Dec 2019$ | |
|---|---|---|
| Profit/(loss) after income tax attributable to the owners of SciDev Limited | 427,450 | (191,233) |
| Number | Number | |
| Weighted average number of ordinary shares used in calculating basic earnings per share | 150,540,455 | 118,065,887 |
| Weighted average number of ordinary shares used in calculating diluted earnings per share | 150,540,455 | 118,065,887 |
| Cents | Cents | |
| Basic earnings per shareDiluted earnings per share | 0.280.28 | (0.16)(0.16) |
Note 19. Share-based payments
On 16 December 2020, SciDev Limited issued 1,408,400 performance rights under the SciDev Limited Employee Share Scheme (SESS) to Executives and staff.
SciDev Limited Directors' declaration 31 December 2020
In the directors' opinion:
- the attached financial statements and notes comply with the Corporations Act 2001, Australian Accounting Standard AASB 134 'Interim Financial Reporting', the Corporations Regulations 2001 and other mandatory professional reporting requirements;
- the attached financial statements and notes give a true and fair view of the consolidated entity's financial position as at 31 December 2020 and of its performance for the financial half-year ended on that date; and
- there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.
Signed in accordance with a resolution of directors made pursuant to section 303(5)(a) of the Corporations Act 2001.
On behalf of the directors
___________________________
Lewis Utting Managing Director
5 February 2021 Sydney

SCIDEV LIMITED
INDEPENDENT AUDITOR'S REVIEW REPORT
To the Members of SciDev Limited
Report on the Half-Year Financial Report
We have reviewed the accompanying half-year consolidated financial report of SciDev Limited, which comprises the consolidated statement of financial position as at 31 December 2020, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half-year ended on that date, notes comprising summary of significant accounting policies and other explanatory information, and the directors' declaration comprising SciDev Limited and the entities it controlled at the half-year's end or from time to time during the half-year.
Directors' Responsibility for the Half-Year Financial Report
The directors of SciDev Limited are responsible for the preparation of the consolidated half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the Corporations Act 2001 and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.
Auditor's Responsibility
Our responsibility is to express a conclusion on the consolidated half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 Review of a Financial Report Performed by the Independent Auditor of the Entity, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the Corporations Act 2001 including: giving a true and fair view of the Group's financial position as at 31 December 2020 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001. As the auditor of SciDev Limited ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.
A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.


SCIDEV LIMITED
INDEPENDENT AUDITOR'S REVIEW REPORT (continued)
Independence
In conducting our review, we have complied with the independence requirements of the Corporations Act 2001. We confirm that the independence declaration required by the Corporations Act 2001, which has been given to the directors of SciDev Limited, would be in the same terms if given to the directors as at the time of this auditor's review report.
Conclusion
Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of SciDev Limited is not in accordance with the Corporations Act 2001 including:
- giving a true and fair view of the Group's financial position as at 31 December 2020 and of its performance for the half-year ended on that date; and
- complying with Accounting Standard AASB 134 Interim Financial Reporting and the Corporations Regulations 2001.
Rothsay Chartered Accountants
Frank Vrachas Partner
Sydney, 05 February 2021